$30mn round supports PTC's ataluren trial but further funding or partner needed
This article was originally published in Scrip
Executive Summary
PTC Therapeutics closed a $30 million funding round to start the private South Plainfield, New Jersey company's Phase III clinical trials for the protein restoration therapy ataluren as a treatment for nonsense mutation Duchenne/Becker muscular dystrophy (nmDBMD) and cystic fibrosis (nmCF).